ヤマナカ　ヒサシ   Yamanaka Hisashi   山中　寿    所属   医学部 医学科（東京女子医科大学病院）    職種   客員教授
論文種別	原著
言語種別	英語
査読の有無	査読なし
表題	Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naïve patients with rheumatoid arthritis: Post-hoc subgroup analysis of the ORIGAMI study.
掲載誌名	正式名：Modern rheumatology 略　 称：Mod Rheumatol ISSNコード：14397609/14397595
巻・号・頁	33(2),pp.271-278
著者・共著者	Azuma Takanori, Misaki Kenta, Kusaoi Makio, Suzuki Yoko, Higa Shinji, Kumon Yoshitaka, Yoshitama Tamami, Naniwa Taio, Yamada Shinsuke, Okano Tadashi, Takeuchi Kimihiko, Ikeda Kei, Higami Kenshi, Inoo Masayuki, Sawada Tetsuji, Kang Chonte, Hayashi Masatoshi, Nagaya Yuko, Hagiwara Takafumi, Shono Eisuke, Himeno Shinkichi, Tanaka Eiichi, Inoue Eisuke, Yoshizawa Yuri, Kadode Michiaki, Yamanaka Hisashi, Harigai Masayoshi
発行年月	2023/03
概要	OBJECTIVES:We performed post-hoc analyses of the ORIGAMI study to investigate whether concomitant methotrexate (MTX) influences the clinical outcomes of abatacept in biologic-naïve patients with rheumatoid arthritis.METHODS:Enrolled patients (n = 325) were divided into two groups according to whether abatacept was prescribed without (MTX-) or with (MTX+) concomitant MTX. We compared the changes in Simplified Disease Activity Index (SDAI), Disease Activity Score-28 with C-reactive protein (DAS28-CRP), and Japanese Health Assessment Questionnaire (J-HAQ) through to 52 weeks of treatment, the abatacept retention rate, and safety.RESULTS:At Week 52, the mean SDAI (8.9 vs. 8.8), DAS28-CRP (2.6 vs. 2.6), and J-HAQ (0.92 vs. 0.91) scores were comparable in the MTX- (n = 129) and MTX+ (n = 150) groups. Multivariable logistic regression revealed no significant association between MTX use and SDAI (low disease activity) or J-HAQ (minimum clinically important difference). The abatacept retention rates, estimated using the Kaplan-Meier method, were 73.2% and 66.7% in the MTX- and MTX+ groups, respectively. Adverse events occurred in 47.5% (of 139) and 52.2% (of 159) of patients in the MTX- and MTX+ groups, respectively.CONCLUSION:The effectiveness and safety of abatacept appeared comparable with or without concomitant MTX in this real-world clinical setting.
DOI	10.1093/mr/roac032
PMID	35389481